Jinhgui Zhang named first chair of Department of Computational Biology at St. Jude

Share on facebook
Share on twitter
Share on linkedin
Share on email
Share on print

JINGHUI ZHANG was named as the first chair of the Department of Computational Biology at St. Jude Children’s Research Hospital. She will hold the St. Jude Endowed Chair in Bioinformatics.

The department will occupy an entire floor in the Kay Research and Care Center, the newest building on the St. Jude campus. The 28,700-square-foot space will be named the Brooks Brothers Computational Biology Center and hold both laboratories and offices. It will also house a genome sequencing laboratory. The department plans to grow to include nine faculty members during the next several years.

“Dr. Zhang has created new computational methods for analyzing genomic data, leading to new directions in research involving high-risk leukemia, brain and solid tumors,” said James Downing, St. Jude president and CEO.

Five years ago, the hospital launched the St. Jude-Washington University Pediatric Cancer Genome Project to map the genomes of childhood cancers. Data generated from the project, 100 trillion-plus pieces, encompass the complete normal and cancer genomes of 700 children and adolescents with 23 different childhood cancers.

Zhang joined St. Jude in 2010, leading the effort to analyze PCGP data and the creation of several new computational tools that have been adopted by biologists worldwide.

Her work has helped define the landscape of mutations that underlie pediatric cancers, resulting in the identification of new pediatric cancer genetic subtypes, insights into cancer-drug resistance and metastatic behavior, and new therapeutic targets against which drugs can be developed.

Prior to St. Jude, Zhang led genetic variation analysis of the first assembled human genome. She also contributed to key discoveries in the pilot phases of the NCI’s Cancer Genome Atlas Project and the Therapeutically Applicable Research to Generate Effective Treatment initiative.

YOU MAY BE INTERESTED IN

Shearwood McClelland III’s grandfather was a ditchdigger who dreamed that his six Black daughters would become doctors. McClelland’s mother did not disappoint—she became the first Black woman board-certified in maternal fetal medicine in the history of the United States.  Now, McClelland is the chief medical officer of Cancer Health Equity at the University of Oklahoma...

As oncology enters a new era of precision medicine, the Food and Drug Administration’s evolving biomarker strategy aims to ensure that life-saving therapies are tailored to individual patient needs, fostering safer and more effective treatments.  Historically, therapies were approved with broad indications based on overall efficacy, even when outcomes for biomarker-positive and -negative patients were...

In the evolving landscape of pediatric oncology, survivorship research has become an essential component of our mission to improve long-term patient outcomes. At City of Hope, we are focused on not only curing childhood cancers but also ensuring that survivors live the healthiest lives possible. A significant part of my research has been dedicated to mitigating the long-term toxicities of cancer therapy—particularly cardiovascular complications that can arise decades after treatment.

Never miss an issue!

Get alerts for our award-winning coverage in your inbox.

Login